Literature DB >> 35482195

Guidelines, Strategies, and Principles for the Directed Evolution of Cross-Reactive Antibodies Using Yeast Surface Display Technology.

Sara Linciano1, Ee Lin Wong1, Ylenia Mazzocato1, Monica Chinellato1,2, Tiziano Scaravetti1, Alberto Caregnato1, Veronica Cacco1, Zhanna Romanyuk1, Alessandro Angelini3,4.   

Abstract

The ability of cross-reactive antibodies to bind multiple related or unrelated targets derived from different species provides not only superior therapeutic efficacy but also a better assessment of treatment toxicity, thereby facilitating the transition from preclinical models to human clinical studies. This chapter provides some guidelines for the directed evolution of cross-reactive antibodies using yeast surface display technology. Cross-reactive antibodies are initially isolated from a naïve library by combining highly avid magnetic bead separations followed by multiple cycles of flow cytometry sorting. Once initial cross-reactive clones are identified, sequential rounds of mutagenesis and two-pressure selection strategies are applied to engineer cross-reactive antibodies with improved affinity and yet retained or superior cross-reactivity.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antibody engineering; Combinatorial library screening; Cross-reactivity; Directed evolution; Multispecificity; Promiscuity; Protein recognition; Yeast surface display

Mesh:

Substances:

Year:  2022        PMID: 35482195     DOI: 10.1007/978-1-0716-2285-8_14

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  29 in total

Review 1.  Engineering antibodies by yeast display.

Authors:  Eric T Boder; Maryam Raeeszadeh-Sarmazdeh; J Vincent Price
Journal:  Arch Biochem Biophys       Date:  2012-03-19       Impact factor: 4.013

2.  Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin.

Authors:  Consuelo Garcia-Rodriguez; Raphael Levy; Joseph W Arndt; Charles M Forsyth; Ali Razai; Jianlong Lou; Isin Geren; Raymond C Stevens; James D Marks
Journal:  Nat Biotechnol       Date:  2006-12-17       Impact factor: 54.908

Review 3.  The state-of-play and future of antibody therapeutics.

Authors:  Zehra Elgundi; Mouhamad Reslan; Esteban Cruz; Vicki Sifniotis; Veysel Kayser
Journal:  Adv Drug Deliv Rev       Date:  2016-12-02       Impact factor: 15.470

4.  Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

Authors:  Wei-Ching Liang; Xiumin Wu; Franklin V Peale; Chingwei V Lee; Y Gloria Meng; Johnny Gutierrez; Ling Fu; Ajay K Malik; Hans-Peter Gerber; Napoleone Ferrara; Germaine Fuh
Journal:  J Biol Chem       Date:  2005-11-07       Impact factor: 5.157

5.  Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin.

Authors:  C Garcia-Rodriguez; I N Geren; J Lou; F Conrad; C Forsyth; W Wen; S Chakraborti; H Zao; G Manzanarez; T J Smith; J Brown; W H Tepp; N Liu; S Wijesuriya; M T Tomic; E A Johnson; L A Smith; J D Marks
Journal:  Protein Eng Des Sel       Date:  2010-12-13       Impact factor: 1.650

6.  Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells.

Authors:  Chingwei V Lee; Sarah G Hymowitz; Heidi J Wallweber; Nathaniel C Gordon; Karen L Billeci; Siao-Ping Tsai; Deanne M Compaan; Jianping Yin; Qian Gong; Robert F Kelley; Laura E DeForge; Flavius Martin; Melissa A Starovasnik; Germaine Fuh
Journal:  Blood       Date:  2006-07-13       Impact factor: 22.113

7.  Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent.

Authors:  Séverine Fagète; Ulla Ravn; Franck Gueneau; Giovanni Magistrelli; Marie H Kosco-Vilbois; Nicolas Fischer
Journal:  MAbs       Date:  2009 May-Jun       Impact factor: 5.857

8.  Beyond natural antibodies: the power of in vitro display technologies.

Authors:  Andrew R M Bradbury; Sachdev Sidhu; Stefan Dübel; John McCafferty
Journal:  Nat Biotechnol       Date:  2011-03       Impact factor: 54.908

9.  Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis.

Authors:  Alessandro Angelini; Yoshishige Miyabe; Daniel Newsted; Byron H Kwan; Chie Miyabe; Ryan L Kelly; Misha N Jamy; Andrew D Luster; K Dane Wittrup
Journal:  Nat Commun       Date:  2018-04-13       Impact factor: 14.919

Review 10.  Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.

Authors:  Mohamed A Alfaleh; Hashem O Alsaab; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Martina L Jones; Stephen M Mahler; Anwar M Hashem
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.